We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In its complaint, Acuitas argues that Arbutus and Genevant had nothing to do with the vaccine’s success and only sued after the Pfizer/BioNTech COVID-19 vaccine achieved “worldwide commercial success.” Read More
New York-based drug discovery company Volastra Therapeutics has signed a deal with Bristol Myers Squibb (BMS) potentially worth up to $1.1 billion to create new medicines for undisclosed targets. Read More
AstraZeneca (AZ) has agreed to pay Chugai Pharmaceutical $775 million to resolve allegations that AZ’s rare disease immunotherapy, Ultomiris (ravulizumab), infringed on the Tokyo-based company’s patents. Read More